Migalastat (INN/USAN), or 1-deoxygalactonojirimycin, trade name Galafold (formerly known as Amigal) is a drug for the treatment of Fabry disease, a rare genetic disorder. It was developed by Amicus Therapeutics. The US Food and Drug Administration (FDA) assigned it orphan drug status in 2004, and the European Committee for Medicinal Products for Human Use (CHMP) followed in 2006. The European Commission approved the drug in May 2016.
